Recombinant asparaginase launched for leukaemia

Spectrila is a recombinant preparation of the enzyme asparaginase, licensed as a component of antineoplastic combination therapy for acute lymphocytic leukaemia in both adults and children. It is administered by intravenous infusion every three days with the dose depending on patient's age and body surface area.

Further information
View Spectrila drug record
Summary of Product Characteristics
Manufacturer: Medac

The amino acid asparagine is needed for cellular protein synthesis. Lymphocytic leukaemia cells are unable to synthesise asparagine as well as normal cells, so they require the extracellular environment to provide them with the amino acid. Asparaginase hydrolyses asparagine to aspartic acid and ammonia, thus depriving the tumour cells of their asparagine supply and ultimately causing cell death.

Asparaginase produced by the bacterium Dickeya dadantii (formerly Erwinia chrysanthemi) is already used in the treatment of acute lymphocytic leukaemia as Erwinase (crisantaspase). A pegylated form of the enzyme derived from E. coli, pegaspargase (Oncaspar), is also available but currently unlicensed.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more